Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer

NCT03423199 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT03423199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03423199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Lead sponsor
National Cancer Center, Japan
Phase
Phase 3
Overall status
Unknown status
Start date
February 9, 2018
Completion date
September 30, 2025
Enrollment
180 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms